Catalyst Pharmaceuticals, Inc.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. carries a market capitalization of 2.62B, placing it among publicly traded companies globally. Its enterprise value stands at 1.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Catalyst Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for August 12, 2026.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. has 122.18M shares outstanding.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 13.69. The price-to-sales ratio is 5.08, and the price-to-book ratio stands at 2.99.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Catalyst Pharmaceuticals, Inc. trades at an EV/FCF ratio of 10.91, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.96B versus a market cap of 2.62B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. maintains a current ratio of 7.10, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Catalyst Pharmaceuticals, Inc. posted a return on equity (ROE) of 24.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 21.68 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.52, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.42, useful for judging operating efficiency across full business cycles. The company generates approximately 2.85M in revenue per employee across its workforce of 181.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.06 indicates how many times Catalyst Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Catalyst Pharmaceuticals, Inc. recorded 65.00M in income tax expense. That works out to an effective tax rate of 25.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 256.47M, leaving 191.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 14, 2026, Catalyst Pharmaceuticals, Inc.'s stock has gained approximately 49.27% over the past 52 weeks. The 50-day moving average sits at 27.11, while the 200-day moving average is 21.83.

Over the twelve months ended March 31, 2026, Catalyst Pharmaceuticals, Inc. generated 516.43M in revenue and converted that into 191.47M in net income, yielding earnings per share of 1.50. EBITDA reached 264.57M, while operating income came in at 231.54M.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. holds 653.89M in cash and equivalents against 2.32M in total debt, resulting in a net debt position of -653.89M. Total book value stands at 876.08M, with working capital of 698.99M providing operational flexibility.

Catalyst Pharmaceuticals, Inc. produced 180.13M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -73,533.50 in capital expenditures, free cash flow totaled 180.05M - equivalent to 1.47 per share.

Over the twelve months ended March 31, 2026, Catalyst Pharmaceuticals, Inc. posted a gross margin of 85.96, reflecting its pricing power and cost economics. The operating margin of 44.83 and net profit margin of 37.08 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 6.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Catalyst Pharmaceuticals, Inc. shareholders.

As of March 31, 2026, Catalyst Pharmaceuticals, Inc. has an Altman Z-Score of 16.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.